Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences' Schumacher upbeat on market potential for its life science tools

Schumacher explained how the group now had six salespeople, and four new instruments ready to come out
Pressure BioSciences' Schumacher upbeat on market potential for its life science tools
The firm's instruments allow researchers to crack open cells

Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher told a recent interview in New York that he believes the market opportunity for the group's tools, which prepare samples, runs into multi billions of US dollars.

"We think there's at least 500,000 researchers and at least 80,000 labs that can use of our system," he told the SNNLive video interview.

WATCH IT HERE...

"Right now we are in about 165 labs of the 80,000. We are a small company. We've had one salesperson for the last nine years. We've had minimal money to develop things. We had one instrument that was run by a microprocessor. Things have really changed for us in the last year."

Schumacher explained how the group now had six salespeople, with four new instruments that are ready to come out on top of the one it already had.

"We now have a brand new instrument that is computer driven, not run by a microprocessor, has tremendous software."

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

Last week, Pressure said it was to collaborate with Phasex Corporation to combine its ultra shear technology with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including  medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

Pressure Biosciences's Schumacher has also conducted an interview with NetworkNewsWire (NNW), a financial news and publishing company.

WATCH IT HERE.

"We supply instruments and consumables to life science laboratories all over the world," says Schumacher.

"These are the laboratories that are aggressively looking for the next billion-dollar drug, the next cure, the next preventive strategy, the next vaccine."

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use